Additional Relevant Details Tivantinib (ARQ 197) is an oral, ATP-independent MET inhibitor with activity in MET-High patients in four randomized, placebo controlled studies in: - Hepatocellular Carcinoma (HCC): ARQ 197-215 double-blind randomized phase 2 study in 107 second-line HCC patients with tivantinib vs placebo1 - Non-squamous, non small cell lung cancer (NSCLC): MARQUEE phase 3 study in 1048 pre-treated non-squamous NSCLC patients with erlotinib plus tivantinib vs erlotinib plus placebo2 - Colorectal cancer (CRC): ARQ 197-252 double-blind randomized phase 2 study in 120 metastatic pre-treated CRC patients with irinotecan plus cetuximab plus tivantinib vs irinotecan plus cetuximab plus placebo3 - Castration-resistant prostate cancer (CRPC): An NIH-sponsored double-blind randomized phase 2 study in 80 metastatic CRCP patients with tivantinib vs placebo4